Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...

To describe the use of double-lumen venovenous (VVDL) extracorporeal membrane oxygenation (ECMO) with cephalic draining cannula (VVDL+V) as a primary approach for all neonatal respiratory diagnoses ...

Global ECMO Market OverviewThe global Extracorporeal Membrane Oxygenation market is projected to register steady growth of approximately 4% to 6% over the next five years, supported by the increasing ...

The current trend of using two cannulas to place most newborns in respiratory failure on life-sustaining ECMO, one in the right internal jugular vein and a second in the right common carotid artery, ...

Registry data reaffirmed extracorporeal membrane oxygenation (ECMO) as a reasonable strategy for COVID-19 patients with severe respiratory problems, with most survivors discharged home and several ...

NEWARK, Del, Dec. 13, 2022 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global arterial cannula market to augment at a 6.6% CAGR from 2022 to 2032. By the end of the said ...

The global arterial cannula market has witnessed remarkable growth, reaching a market value of USD 21 billion in 2023. With a robust compound annual growth rate (CAGR) of 6.6%, this market is ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...

Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days' use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow ...